The expression pattern of tight junction (TJ) proteins is frequently disrupted in epithelial tumors. In particular, isoform-and organ-specific alterations of claudins have been detected in human cancers, highlighting them as interesting tools for the prognosis or treatment of various carcinomas.
Introduction
Tight junctions (TJ) are the most apical component of cell/cell complexes, constituting a continuous seal around the apical cell border and playing a critical role in regulating the balance between differentiation, proliferation and cell death [1, 2] . They are made up of at least three types of integral transmembrane proteins, which are responsible for the formation of a network of intramembrane fibrils, and by a growing number of cytoplasmic TJ plaque proteins connecting the transmembrane proteins to the cytoskeleton and serving as a platform for cell signaling and protein trafficking [3] . Among the integral proteins cooperating to form TJ, the recent literature describes the modulation of claudins during oncogenic transformation, indicating that they could play an important role in influencing tumor progression and invasion [4, 5] . Recent reports suggest that TJ protein expression could be disrupted before the onset of epithelial/mesenchyme transition [6] , but it remains unclear at what stage of tumor development alterations of claudin expression occur, and whether their disruption is associated with tumor progression. In the urothelial bladder, TJs are formed between adjacent umbrella cells, where they play an important role in the separation between the basolateral membrane and the apical membrane, where specific proteins named uroplakins create a barrier against transcellular ion permeability [7] . Several TJ proteins have been detected in the urothelium, among them claudins 1, 4, 8 and 12 [8] . Two of these proteins, claudin-1 and claudin-4, are expressed at TJ and along the cell/cell membrane of umbrella cells, but are also detected in intermediate and basal cells [8] [9] [10] , where their function remains unclear. In addition, preliminary results from our group indicated that urothelial cells also expressed significant levels of claudin-7, a ubiquitous claudin isoform previously shown to localise both at tight junctions and along the basolateral membrane of epithelial cells in other tissues [11] . The expression of claudins 1, 4 and 7 was shown to be disrupted in other types of cancer [12] [13] [14] . Indeed, overexpression of the CLDN-4 gene, sometimes coupled to cytoplasmic relocalization has been detected in ovarian or pancreatic carcinomas [15, 16] , and its interaction with the Clostridium Perfringens Enterotoxin (CPE) offers interesting prospects for cancer treatment [17, 18] . Furthermore, claudin-1 was recently shown to regulate cellular transformation and metastatic behavior in colon cancer [19] and to constitute a promising prognostic marker for stage II colon cancer [20] . Claudin-7 overexpression was detected in hepatocellular carcinoma, as well as early gastric cancers [13, 21] , while methylation-dependent down-regulation of this protein seems correlated with the progression of breast carcinoma [22] . However, the contribution of these proteins to tumorigenesis of the bladder is still unknown. In fact, very little data is currently available on the molecular events related to TJ regulation in urothelial cancer, although a decreased number of TJ strands was detected by freeze fracture electron microscopy twenty years ago [23] in transitional cell carcinomas of the bladder. In view of the critical role played by TJ in the protection against toxins and proinflammatory agents contained in urine, and since claudins-1, -4 and -7 have been identified as relevant targets in other types of carcinomas, the purpose of this study was to analyze the expression pattern of these three proteins in human bladder carcinoma. Our results demonstrate the occurrence of profound alterations in the expression and localisation of claudin-4 in bladder carcinoma. In addition, the methylation profile of CLDN-4 gene coding sequence was found to regulate the expression level of claudin-4 in the bladder urothelium, and to be involved in the profound down-regulation of the protein in advanced bladder cancer.
Materials and methods

Antibodies
Anti-claudin-1 , -claudin-4, and claudin-7 antibodies were from Zymed (San Francisco, CA), pancytokeratin, smooth muscle actin, and desmin from Sigma (St Quentin Fallavier, France). Alexa Fluor 488-labelled was from Molecular Probes, while Cy3-labelled and HRP-conjugated antibodies were from Chemicon, (Mundolsheim, France). Antibodies for cis-Golgi and trans-Golgi markers (GM130 and p230) and endosomal vesicle proteins (EEA-1, Rab 7, CD63) were provided by Drs. C. Brock, S. Roche and M.
Vidal.
Primary cultures
Tumor samples were cut into 1 mm pieces and digested for 10 min at 37°C, in DMEM containing 1 mg/ml collagenase P (Roche Diagnostics, Meylan, France), 1 mg/ml protease and 0.8 mg/ml type I Soybean Trypsin Inhibitor (Sigma). Undigested tumor pieces and dissociated cells were resuspended in growth medium and seeded on collagen IV-coated dishes (Sigma). When needed, cells were lysed after 4-day treatments in growth medium with or without 10 µM 5-aza-deoxycytidine (5-aza-CdR) (Sigma), before extracting proteins, genomic DNA and RNA, as described elsewhere.
Cell culture and transient transfections
HT-1376 cells were maintained at 37°c in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (Eurobio, Les Ulis, France), 1% L-glutamine, 1% MEM non-essential Amino Acid 
Trans-epithelial resistance (TER) measurement
TER was measured as described in [24] . Cells (1x10 5 cells/well) were seeded in the apical compartment of 0.4 µm pore size cell culture insert (BD, Le pont de Claix, France). Inserts were placed in 12-well tissue culture plates (BD), containing 1ml of medium in the basolateral compartment and incubated at 37°C with 5% CO 2 . In all experiments, epithelial cells were grown to confluence on cells inserts. Transepithelial resistance was monitored as an indication of TJ formation and epithelial monolayer integrity using a Millicell-ERS Voltohmmeter, (Millipore, Molsheim, France). Electrical resistance measurements were taken daily in two sites on each side of the transwell membrane, in order to ensure that measurements reflected as well as possible the resistance across the whole monolayer surface. The mean of these two measurements was calculated, and results were expressed as Ohmsx cm 2 , after subtracting the values for the resistance of the membrane alone.
Human tumor samples
Specimens of papillary bladder carcinomas and macroscopically and histologically normal urothelium from 39 patients were obtained after trans-urethral bladder resection or cystectomy, according to French government regulations and local committee guidelines. Tumor samples were provided by the pathologist and represented mostly the exophytic component of both early and late stage tumors. Tumors were grouped into superficial (stage pTa) or invasive (stage ≥ pT1) according to the stages described in the TNM 2002
classification [25] , and were graded following the 1998 update of the World Health Organization/International Society of Urologic Pathologists grading system [26] into well-differentiated (grade G1), moderately differentiated (grade G2) or poorly differentiated (grade G3). Sections were prepared from frozen tumor samples, and immunohistochemical detection of claudins was performed on randomly chosen sections from three areas of each sample. The epithelial content was assessed by staining adjacent sections with hematoxylin/eosin. Other sections were lysed for Western blot analysis and, when sufficient quantities were available, the homogeneity of urothelial/mesenchymal tissue proportions within the samples was confirmed by probing WB with antibodies against stromal markers (desmin and smooth muscle actin).
Whenever possible, adjacent sections were also used for RNA extraction and genomic DNA preparations.
Immunoblotting
Protein lysates were prepared at 4°C in RIPA buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% Na-deoxycholate, 50mM NaF, 40 mM beta-glycerol phosphate, 10 mM HEPES, pH 7.3, 5 mM EDTA, 0.2mM Na-orthovanadate, 1mM DTT, 1% Protease Inhibitor Cocktail (Sigma)) from approximately 50 tissue cryosections per patient (20µl/mg tissue), or from confluent cell cultures. Proteins (20 µg) were separated on 12% SDS-polyacrylamide gels, and transferred onto nitrocellulose membranes using a semi-dry Western blotting apparatus from Biorad (3 mA/cm 2 , 40min). After saturation in PBS,5% milk, 0.1% Tween20, membranes were incubated overnight at 4°C with the primary antibodies (antibody dilutions: claudin-1, -4 and -7 (1/500); actin (1/5000); smooth muscle actin and desmin (1/1000)). After incubating with HRP-conjugated secondary antibodies (anti-rabbit or anti-mouse IgG, 1/5000 dilution), proteins were visualized using the ECL Plus system (Amersham, Orsay, France).
Immunofluorescence
Sections were fixed in 1% paraformaldehyde, permeabilized and incubated with 50mM NH 4 Cl to reduce background staining. After saturation with PBS, 5% BSA, 0.3% gelatin, primary antibodies were incubated overnight at 4°C (claudin-1 and -4 antibodies, 1/100 dilution; claudin-7 antibody, 1/50). Tissue sections were then washed with PBS and incubated with Alexa Fluor 488-and/or Cy3-coupled secondary antibodies
(1/500 dilution). The samples were mounted in mowiol (Aldrich, Lyon, France). Slides were observed using a Biorad MRC 1024 confocal microscope. "Blind" quantification of the immunofluorescence data was performed by two independent observers, and scoring was done in two ways: (a) In the scoring for staining intensity, 0 represented weaker staining in the tumor than in the control urothelium, 1 represented similar intensity in both samples, and 2 represented higher intensity in the tumor sample; (b) Intracellular localization of the proteins, irrespective of the overall intensity, was determined with a 4-point scoring system for each cell compartment (membrane, cytoplasm, and nucleus), where 0 meant that the protein was absent from the compartment, 1 that less than 30% of cells expressed the protein in this compartment, 2 that 30-70% of cells express the protein in this compartment, and 3 that more than 70% of cells expressed the protein in the compartment of interest.
Transmission electron microscopy and immunogold detection of claudins
For ultrastructural determination of healthy or tumoral bladder tissue structures, tissue samples were fixed overnight at 4°C in a solution of 3.5% glutaraldehyde in PBS (0.1M, pH 7.4). After rinsing in PBS, postfixation was performed for 1h at room temperature in 2% osmic acid. After 2 rinses in PBS, tissues were dehydrated using a gradient of increasing ethanol solutions (30-100%), then embedded in Spurr. Thin sections (85nm, Leica-Reichert Ultracut E) were collected at different levels of each block, and counterstained with uranyl acetate (1.5% in 70% ethanol) and lead citrate, and observed using a Hitachi 7100 transmission electron microscope.
For immunogold detection of claudins, tissues were fixed overnight at 4°C in PBS containing 3% paraformaldehyde/0.1% glutaraldehyde. Dehydration was performed using 2 consecutive 15 min incubations in 30, 50, then 70% ethanol solutions. Tissues were then incubated in 1.5% uranyl acetate in 70% Ethanol for 30 min at room temperature, then for 3 consecutive 15 min periods in 80% followed by 95% ethanol. After embedding in LR White resin, 85nm sections were collected using an ultramicrotome on Nickel grids.
Sections were then incubated for 2h at room temperature in PBS + 0.5% freshwater fish gelatin + 1% BSA ("incubation buffer"), then overnight at 4°C with the relevant primary antibody (claudin -1 or -4, dilution 1/20; claudin 7, dilution 1/10). After 5 x 12min washes, sections were incubated for 50 min at room temperature with secondary antibodies (anti-mouse or anti-rabbit IgG coupled to 15nm gold beads, dilution 1/20, Aurion, France), washed again (5 x 12 min), incubated for 2min in 2% glutaraldehyde, and rinsed briefly with filtered milliQ water. (All washes and antibody dilution were made in the incubation buffer described above). Observation was performed using a Hitachi 7100 transmission electron microscope.
Sequencing of CLDN4 coding sequence
The genomic DNA was isolated from twelve patient's tumour samples using the QIAamp DNA Mini kit 
RNA extraction and mRNA quantitation
Frozen tissue samples were first lysed at 4°C using a Mixer Mill MM 300 in RNeasy Lysis buffer (RLT buffer) (Qiagen, Hilden, Germany), using sterile steel beads. Total RNA was then extracted from tumor or normal samples using the RNeasy Mini kit (Qiagen, Hilden, Germany), and RNA quality was controlled 
Detection of CLDN-4 gene methylation
The CLDN-4 genomic sequence was searched for the presence of CpG islands using the CpG Island Searcher (http://www.cpgislands.com) [27] . Genomic DNA was extracted from tissues or primary tumor cells using the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). 0.5 to 1 µg genomic DNA was modified with sodium bisulfite using the CpGenome DNA Modification kit (Chemicon, Temecula, USA). Two methylation-specific PCR (MSP) reactions were then performed on each sodium bisulfite-treated genomic DNA sample, using primers specific for the methylated (5'-TTATGGGGTTATAGGTAATGGGTATC-3'
(UMR)). Primers were designed using MethPrimer (http://itsa.ucsf.edu/~urolab/methprimer) [28] . MSP conditions were: 95°C for 5 min, followed by addition of 2.5 units GoldStar DNA Polymerase (Eurogentec, Seraing, Belgium); 40 cycles of 95°C/30 sec, 55°C/30 sec, 72°C/30 sec; final extension at 72°C/4 min. The PCR products were then run on ethidium bromide-stained agarose gels.
Mouse tissues and histochemistry
Dnmt3a over-expressing mice were generated by a knock-in gene targeting method to introduce a cDNA fragment encoding the full-length Dnmt3a protein into the endogenous A33 antigen locus, in view of the tissue-specific nature of this gene. The A33 antigen is a transmembrane glycoprotein prominently expressed in adults by intestinal epithelial cells, as well as in the bladder urothelium [29, 30] . In the mice used here, transcription at the targeted locus produces a bi-cistronic mRNA, which encodes both A33 antigen and Dnmt3a. Translation of the Dnmt3a cistron is initiated at an internal ribosome entry site (IRES) (M.Samuel and M. Ernst, in preparation). The resulting mice over-express Dnmt3a within the intestinal and bladder epithelium. After bladder dissection, paraffin embedding, tissue sectioning and hematoxylin/eosin staining were performed as in [31] . Following dewaxing and hydration, paraffin tissue sections were pretreated with peroxidase for 20 min at room temperature. Antigen was retrieved by boiling samples for 20 min in 10mM
Tris -1 mM EDTA, pH 9. Slides were allowed to cool down to room temperature, and incubated overnight at 4°C with antibodies in PBS +0.05% BSA. In all cases, the Envision+ kit (DAKO) was used as a secondary reagent. Stainings were developed using DAB (Sigma) and slides were counterstained with hematoxylin and mounted.
Statistical analysis
Optimal exposure times of membranes were used for each patient, and protein expression was quantified using NIH Image 1.62, and adjusted for background noise and protein loading. The ratio of expression in tumor vs. healthy samples was calculated for each patient from the results of three experiments. For each patient, a one-sample t-test was used to determine whether the mean ratio was significantly different from the theoretical value of 1 (µ) (which reflects a similar expression in tumor and healthy samples). The formulation of this test was: t X ? ? / S / n ? ?
(X bar represents the mean ratio, S the standard error, and n the number of replicates for each sample, n=3). The ratio was considered as significantly different from 1 when p<0.05. Associations between claudin expression or localization and clinical or pathological data were analyzed using Fischer's exact test, using SAS 9.1 for Windows (Cary, NC, USA). Student's t-test was used in order to determine the statistical significance of differences between primary cell cultures transfected or not with claudin-4 siRNA.
Results
Alterations of CLDN protein expression in bladder tumor samples
Post-transcriptional and post-translational events are essential to the regulation of claudin expression and functions [32, 33] . Here, we first quantified the expression of claudin-1, -4 and -7 proteins in whole lysates from healthy urothelium and bladder tumor samples of 39 patients using Western blotting. Significant variations of claudin expression were detected between control and tumor samples ( Figure 1A ), independently of variations in the proportion of urothelium and stroma within each sample, which were assessed by probing the same membranes with antibodies against smooth muscle actin (SMA) and desmin 
Alteration of claudin-4 mRNA expression in bladder tumor samples
We initially sought to determine whether the alterations of claudin-4 expression detected in bladder carcinoma could be due to mutations within the promoter region or the coding sequence of the CLDN-4
gene. We therefore amplified by PCR a genomic DNA region starting 1kb upstream of the transcription initiation site and including the coding sequence of this single-exon gene. Sequencing of these regions was performed from the genomic DNA of 12 patients with bladder carcinoma (7 displaying claudin-4 downregulation and 5 with overexpression of the protein), but sequence alignment showed that no mutations were present in any of the samples analysed (data not shown). We then quantified the expression of claudin-4
mRNA from healthy and tumor bladder samples where enough remaining material was available, in order to confirm whether claudin-4 down-regulation was due to a transcriptional mechanism. Total RNA was extracted from 9 patients samples, and expression of claudin-4 mRNA was quantified using Real-Time were found to corroborate variations detected at the protein level ( Figure 2C ).
Inhibition of methyl transferases restores claudin-4 expression in primary cultures of human bladder tumor cells
We then decided to assess whether CLDN-4 gene promoter hypermethylation could be responsible for the down-regulation of claudin-4 expression in invasive and high-grade bladder tumors, similarly to what was recently demonstrated in the case of claudin-7 expression in high-grade breast carcinomas [22] . While the 4kb genomic DNA sequence covering the putative promoter and the 5' non-coding region of the CLDN-4
gene lacks CpG islands, we identified a CpG island starting 227nt upstream of, and stretching along, the entire coding sequence of this gene ( Figure 3A) . Based on the stringent criteria for CpG islands put forward by Takai and Jones [34] , this region is likely to constitute a functional CpG island.
In order to assess whether increased methylation could be responsible for the down-regulation of We then examined ifthe causal relationship between increased methylation of the CLDN-4 gene and reduced expression of the protein was relevant in vivo, and whether it could have a role to play in the physiological regulation of this gene outside of a tumor context. In order to do so, we made use of a mouse knock-in model expressing DNA methyl transferase 3a (Dnmt3a), originally generated in order to study the impact of methylation processes on the intestinal epithelium (M.S.Samuel and M. Ernst, in preparation).
Indeed, in these A33 D3a knock-in mice, Dnmt3a is expressed from the gene locus of the endogenous A33
antigen, a transmembrane protein specifically expressed by epithelial cells in the intestine, but also in the bladder [29] .
This de novo DNA methyl transferase is highly expressed during embryogenesis and has been previously shown to be overexpressed in bladder tumors [35] . It was recently shown to be sensitive to 5-azaCdR [36] , and its activity can be detected in bladder tumor cells, independently from that of the more broadly expressed Dnmt1 isoform [37] . We therefore examined whether overexpression of this DNA methyl transferase in the bladder epithelium was capable of affecting the expression of claudin-4 in vivo.
Although the overall morphology of the bladder urothelium was conserved in A33 D3a mice, umbrella cells appeared less polarized and differentiated than in control mice, as assessed by hematoxylin/eosin staining ( Figure 4A ). These cells displayed characteristically large cytoplasms in the bladder of A33 wt mice, but their overall size was markedly reduced in A33 D3a mice, where they are harder to distinguish from the underlying cell layers ( Figure 4A ). Maximal expression of the transgene was detected in the uppermost layer of the bladder epithelium in A33 D3a mice, corresponding to the umbrella cell layer ( Figure 4B ). In the bladder of control A33 wt mice, regular claudin-4 expression was detected at the TJ of umbrella cells, as well as around the cell membrane of underlying cell layers ( Figure 4C ), as previously described [8] . In A33 D3a mice, although claudin-4 expression appeared normal in basal and intermediate cells, the protein was completely undetectable in umbrella cells, where expression of Dnmt3a was the highest ( Figure 4C ). This effect was not due to a general down-regulation of cell/cell junctions between neighboring umbrella cells, since expression of occludin was still detected at TJ in the bladder of A33 D3a mice. The localization of other junctional proteins such as claudin-7 and E-cadherin was slightly altered in mice overexpressing Dnmt3a but, unlike claudin-4, they were still expressed by umbrella cells in A33 D3a mice ( Figure 4C ).
The methylation profile of the CLDN-4 gene coding sequence is directly correlated to the expression of the protein in human bladder tumors.
Results presented above indicated that increased methylation within the coding sequence of the In genomic DNA extracted from healthy samples, this region was amplified both with primers specific for the unmethylated DNA and with primers targeting the methylated sequence ( Figure 5A) .
Interestingly, the level of amplification with methylation-specific primers was inversely proportional to levels of claudin-4 protein expression in healthy samples (see samples 19H, 39H, 12H and 22H in Figure   5A ), suggesting that variations of methylation levels could play a role in the physiological regulation of claudin-4 expression. Similarly, the relative level of amplification with methylation-specific primers was in Figure 5A ). These results strongly suggested that the methylation level of the CLDN-4 gene coding sequence is correlated to the expression of the protein in the healthy human bladder and in human bladder tumors.
Subcellular distribution of claudins within healthy and tumoral bladder urothelium
In order to establish whether claudin-1 -4 and -7 were still targeted to TJs in human bladder tumors,
we assessed the localization of these proteins in a panel of tumor samples in comparison with healthy bladder urothelium. The three claudin isoforms were detected at the TJ, as well as along the basolateral membrane of most cell layers across the urothelium of all macroscopically healthy bladder samples (Figure 6a-f) , as already described in several species [8] [9] [10] . Claudin-1 immunostaining was stronger in the intermediate and basal urothelial cell layers (Figure 6a, d) , while claudin-4 was prominently expressed in umbrella cells (Figure 6b , e). Claudin-7 was found to be distributed throughout the bladder epithelium (Figure 6c, f) . No significant staining for these claudins was found within the cytoplasm of cells in healthy bladder samples.
The presence of claudins 1, 4, and 7 at the membrane of umbrella cells, but also of intermediate and basal cells, was confirmed using immunogold staining followed by electron microscopy. In umbrella cells, claudin-1 and -4 were expressed along the lateral membrane, including at tight junctions, while claudin-7
was detected predominantly along the lower lateral membrane and the basal membrane (Supplementary Figure S1 ).
In contrast, a loss of membrane localization of claudin-1 and -4 was detected in virtually all bladder tumor samples, albeit to different degrees. Disappearance from the cell membrane was found to be complete in a large proportion of tumors, while residual membrane staining for claudin-1 and -4 was detected in 54%
and 38% of tumor samples, respectively (white arrows in Figure 6j , k, m, q), with a decreasing proportion of cells displaying membrane claudin expression in invasive and high grade tumors. In addition, cytoplasmic immunoreactivity for claudin-1 and -4 was detected in all but three bladder tumor samples, including most superficial and low grade tumors (Figure 6g , h, j, k, n, p, q, s). Cytoplasmic staining was prominant in tumors displaying increased staining intensity when compared to the matching control tissue (Figure 6g , h compared to 6a, b). However, weak cytoplasmic staining was still detected in tumors where the overall staining intensity was decreased (Figure 6n, t) . Finally, the cytoplasmic staining for claudin-1 or -4 was often found to have a speckled pattern (grey arrows in Figure 6 n, s, t), but we were not able to detect any colocalization between these proteins and endosomial and Golgi markers (data not shown). In contrast, fewer disruptions were detected in the distribution pattern of claudin-7. The protein was still localised at the membrane in all the tumor samples analysed, although the membrane staining appeared speckled in high-grade tumors (cf.
white arrowheads in Figure 6o that a similar mechanism could be responsible for their mislocalization in human bladder tumors. Since the establishment of adherens junctions is known to facilitate TJ protein recruitment, and since methylationinduced E-cadherin down-regulation has been described previously in bladder tumors [38] , we analyzed Ecadherin localization in HT-1376 cells. We found that E-cadherin was already present at the plasma membrane of HT-1376 cells without treatment with 5-aza-CdR, suggesting that, in HT-1376 cells at least, Ecadherin expression is not down-regulated by hypermethylation and is properly targeted to the membrane ( Figure 7B ). In addition, this methylation-driven regulation of claudin localization did not reflect a general effect on TJ proteins, since occludin ( Figure 7B ) and ZO-1 (not shown) were properly addressed to the membrane in untreated HT-1376 cells.
Functional consequences of claudin-4 down-regulation in bladder tumors.
We then sought to determine the functional consequences of claudin-4 mislocalization and/or down-regulation in bladder tumors. We initially tried to grow primary bladder tumor cell cultures on suspended Figure 8C ). Levels of ZO-1 remained unchanged and the protein was still targeted to TJs, although the proportion of cytoplasmic ZO-1 appeared slightly higher in cells transfected with claudin-4 siRNA ( Figure   8C ). Furthermore, we found that the down-regulation of claudin-4 prevented the increased polarisation of HT-1376 cells normally seen after 5-aza-CdR treatment (see XZ representations in Figures 7A and 8C ). It is noteworthy that pronounced modification of cellular size and polarization were also detected in umbrella cells of A33 D3a mice, where claudin-4 expression, but not that of claudin-7 or occludin, was down-regulated (see Figure 4A and C). In addition, our results demonstrate that incubation with claudin-4 siRNA largely prevented the increase in TER normally observed in 5-aza-CdR-treated HT-1376 cells, while a control siRNA had no effect ( Figure 8D ). 
Discussion
The first important finding of this study concerned the significant changes of claudin-4 expression potential of pancreatic cancer [39] , whereas overexpression of claudin-3 and -4 promoted ovarian tumor metastasis through increased invasion and survival [40] . Larger patient numbers and a longer follow-up should help to properly assess the evolution of low-stage and low-grade tumors, and to conclude whether claudin-4 has a role to play as a prognostic marker for bladder cancer, similar to that of claudin-1 in stage II colorectal carcinomas [20] .
The pattern of claudin-4 expression in bladder carcinomas identified here is markedly different to that observed in pancreatic and ovarian cancers, where overexpression was the prominent feature [14, 15, 41] .
Early stage bladder tumors were found in the present study to overexpress claudin-4, suggesting that these tumors could be interesting targets for treatment with the Clostridium perfringens enterotoxin (CPE). CPE binds selectively to claudin-3 and -4, thereby mediating cytolysis of cancer cells [16, 17] , and the potential of this therapeutic approach was recently vindicated in vivo on chemotherapy-resistant mammary tumor xenografts [18] . However, we found that all bladder tumors overexpressing claudin-4 display very little membrane staining for this protein, implying that the protein is probably largely inaccessible to the toxin and thereby limiting the potential use of CPE for treatment of superficial bladder cancer.
The sharp down-regulation of claudin-4, detected in invasive and high grade tumors only, is consistent with the recent demonstration that claudin-4 expression decreases the invasive potential of pancreatic cancer cells [39] . Down-regulation of other claudins [2, 10, 41] was detected in gastric or breast cancers, and does not seem to involve genetic alterations [22, 42, 43] . Similarly, our results showed the absence of mutations within the coding sequence of the CLDN-4 gene in all tumors analyzed. In view of the well-documented effects of promoter hypermethylation on gene silencing in cancer [44] , and since hypermethylation of the promoter region was previously found to induce a down-regulation of the CLDN-7
gene in breast carcinoma [22] , we sought to determine whether a methylation process could be responsible carcinoma, mostly due to a gene promoter methylation [22] . Results of the present study therefore suggest that a similar modulation could be responsible for the down-regulation of claudin-7 expression in bladder tumors. However, the populations of tumors displaying claudin-4 and claudin-7 down-regulations were found to overlap only partially, suggesting that the CLDN-4 and CLDN-7 genes could be sensitive to different isoforms of DNA methyl-transferases or, alternatively, that different molecular processes are involved in modulating the sensitivity of these two genes.
In the present work, we also showed in this work that claudin-1 and -4 were mislocalized in 90% of bladder carcinoma samples, including superficial and low-grade tumors. In contrast, the localisation of claudin-7 was largely restricted to the membrane in all carcinoma samples, albeit with a fragmented appearance in high-grade tumors. A pattern of overexpression coupled to abnormal targeting of claudin-1 was identified previously in colon carcinoma [46] , and partial cytoplasmic localization of claudin -4 was previously described, primarily in ovarian cancer [16, 47] . Increased internalization of claudins has recently been demonstrated on MDCK cells [48] and, since both claudins analyzed in this work displayed a speckled cytoplasmic staining profile in some tumor samples, we tried to assess whether they could be colocalized with intracellular vesicles. However, claudin-1 or claudin-4 immunoreactivity did not colocalize with early and late endosomes, or with cis-and trans-Golgi markers (data not shown).
The reasons underlying claudin-4 mislocalization remain unclear. A mutation within the PDZbinding domain of claudin-16 was previously shown to impair its ability to localize at the TJ, resulting in its accumulation in lysosomes [49] . However, we did not detect any mutation within the coding sequence of Immunostaining for claudin-1 (green) and -4 (red) on transverse (a, b, c) and longitudinal sections (d, e, f) from healthy urothelium, or from tumor urothelium at various stages and grades (g-u). White arrows indicate membrane staining, black arrows nuclear staining, and grey arrows point to speckled cytoplasmic staining in tumor samples.
White arrowheads point to areas of irregular staining for claudin-7 in G3 tumors, and grey arrowheads indicate regular claudin-7 staining at the tumor/stroma interface. Bars indicate 40 µm, or 12µm (inset). 
